01—Abstract
Summary
Summary of the 10-Q filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.
The Cigna Group reported a significant increase in net income for the nine months ended September 30, 2025, driven by the absence of a substantial prior-year investment impairment.
Total revenues grew by 12%a year-over-year, largely due to strong performance in Pharmacy revenues, which increased by 17%. This growth was primarily fueled by higher utilization and customer expansion within the Evernorth Health Services segment. However, the Cigna Healthcare segment experienced a revenue decline of 9%, largely attributable to the divestiture of its Medicare Advantage business.
Despite this, the company managed its expenses effectively, with Selling, General, and Administrative (SG&A) expenses remaining relatively flat year-over-year when excluding the impact of strategic optimization programs. The company also strengthened its balance sheet by issuing new senior notes and repaying existing debt, demonstrating a proactive approach to capital management.
02—Key points
Key Highlights
- Total revenues increased by 12% to $202.4 billion for the nine months ended September 30, 2025, compared to the prior year, driven by strong growth in Pharmacy revenues.
- Shareholders' net income saw a substantial increase of 135% to $4.7 billion for the nine months ended September 30, 2025, largely due to the absence of a prior-year investment impairment.
- The divestiture of the Medicare Advantage business impacted Cigna Healthcare's revenues, which decreased by 9% year-over-year for the nine months ended September 30, 2025.
- Evernorth Health Services demonstrated robust growth, with adjusted revenues up 16% and pre-tax adjusted income from operations up 4% for the nine months ended September 30, 2025.
- The company successfully managed its debt, issuing $4.5 billion in new senior notes and repaying $2.0 billion under a term loan facility during the period.
- Selling, General, and Administrative (SG&A) expenses remained flat year-over-year for the nine months, reflecting effective cost management despite strategic investments.
- The company repurchased $2.6 billion of its common stock during the nine months ended September 30, 2025, continuing its capital return strategy.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Cigna Group kept $0.03.
- Revenue$69.75B100.0%
- Cost of revenue−$55.53B79.6%
- Gross profit$14.22B20.4%
- Operating costs−$11.64B16.7%
- Operating income$2.58B3.7%
- Interest, other & tax−$710.0M1.0%
- Net income$1.87B2.7%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 30, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $69.75B$63.69B | +9.5% |
| Cost of Revenue | $55.53B$47.56B | +16.7% |
| Gross Profit | $14.22B$16.13B | −11.8% |
| SG&A Expenses | $3.36B$3.59B | −6.4% |
| Operating Income | $2.58B$2.58B | +0.1% |
| Interest Expense | $363.00M$380.00M | −4.5% |
| Net Income | $1.87B$739.00M | +152.8% |
| EPS (Basic) | $7.02$2.65 | +164.9% |
| EPS (Diluted) | $6.98$2.63 | +165.4% |
| Shares Outstanding (Diluted) | 267.53M281.40M | −4.9% |
05—Questions
Frequently Asked Questions
What was the primary driver of the significant increase in net income for the nine-month period?
The primary driver was the absence of a substantial impairment charge on equity securities (specifically, the investment in VillageMD) that was recorded in the same period last year. This year's results benefited from not having that charge.
How did the divestiture of the Medicare Advantage business affect the company's financial performance?
The divestiture of the Medicare Advantage business led to a decrease in Cigna Healthcare's revenues by 9% for the nine months ended September 30, 2025, compared to the prior year. This also impacted the Medical Care Ratio and SG&A expense ratio within that segment.
What is the outlook for the Evernorth Health Services segment?
The Evernorth Health Services segment continues to show strong growth, with adjusted revenues up 16% and pre-tax adjusted income from operations up 4% for the nine months ended September 30, 2025. This growth is attributed to increased pharmacy utilization, customer expansion, and contract affordability improvements. The company is also investing in new initiatives like a rebate-free model, which may impact short-term profitability but is expected to drive long-term value.
How is Cigna Group managing its debt and capital structure?
Cigna Group actively manages its capital structure. During the period, they issued $4.5 billion in new senior notes and repaid $2.0 billion of a term loan. They also repurchased $2.6 billion of common stock. The company maintains a substantial revolving credit facility and a commercial paper program for liquidity support, and it continues to prioritize capital deployment towards strategic investments, dividends, and share repurchases.
06—Continue